# OnCo record elm-pc-4-orteronel (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/elm-pc-4-orteronel/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "elm-pc-4-orteronel", "NCT01193244" ;
  schema:name "ELM-PC 4"@en ;
  schema:alternateName "ELM-PC 4"@en, "C21004"@en, "orteronel in chemotherapy-naive mCRPC"@en ;
  schema:description "A cleaner version of abiraterone held the cancer back on scans for five extra months and did not make anyone live longer. It is the clearest warning in prostate cancer that scans are not survival."@en ;
  schema:url <https://onco.cc/trials/elm-pc-4-orteronel/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01193244>, <https://doi.org/10.1016/S1470-2045(15)70027-6> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:targets <https://onco.cc/targets/cyp17a1/> ;
  onco:drugs <https://onco.cc/drugs/orteronel/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:terms <https://onco.cc/terms/arpi/>, <https://onco.cc/terms/castration-resistance/> ;
  onco:trials <https://onco.cc/trials/cou-aa-302/>, <https://onco.cc/trials/tasquinimod-10tasq10/> .